These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 29487031)
1. New drugs and perspectives for new anti-tuberculosis regimens. Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031 [TBL] [Abstract][Full Text] [Related]
2. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767 [TBL] [Abstract][Full Text] [Related]
3. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
6. Management of drug resistantTB in patients with HIV co-infection. Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945 [TBL] [Abstract][Full Text] [Related]
7. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712 [TBL] [Abstract][Full Text] [Related]
8. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Seaworth BJ; Griffith DE Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737 [TBL] [Abstract][Full Text] [Related]
9. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. Harausz EP; Garcia-Prats AJ; Seddon JA; Schaaf HS; Hesseling AC; Achar J; Bernheimer J; Cruz AT; D'Ambrosio L; Detjen A; Graham SM; Hughes J; Jonckheere S; Marais BJ; Migliori GB; McKenna L; Skrahina A; Tadolini M; Wilson P; Furin J; Am J Respir Crit Care Med; 2017 May; 195(10):1300-1310. PubMed ID: 27854508 [TBL] [Abstract][Full Text] [Related]
10. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea. Yang JS; Kim KJ; Choi H; Lee SH Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700 [TBL] [Abstract][Full Text] [Related]
11. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs. Sullivan T; Ben Amor Y Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26889711 [TBL] [Abstract][Full Text] [Related]
12. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722 [TBL] [Abstract][Full Text] [Related]
14. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China. He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699 [TBL] [Abstract][Full Text] [Related]
16. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings. Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662 [TBL] [Abstract][Full Text] [Related]
17. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240 [TBL] [Abstract][Full Text] [Related]
18. ▼Bedaquiline for multidrug-resistant tuberculosis. Drug Ther Bull; 2014 Nov; 52(11):129-32. PubMed ID: 25395481 [TBL] [Abstract][Full Text] [Related]
19. New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents. Garcia-Prats AJ; Starke JR; Waning B; Kaiser B; Seddon JA J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S101-S109. PubMed ID: 36314547 [TBL] [Abstract][Full Text] [Related]
20. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. Kwon YS; Jeong BH; Koh WJ Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]